Table 4. Comparison of EGFR T790M detection platforms in tissue.
S.No | Method | Sample | EGFR T790M Detection rate % | Study group | |
---|---|---|---|---|---|
Treatment Naive/Pre-treatment | Post-TKI | ||||
1 | Scorpion ARMS | Tissue N = 29 | 0 | 48.3 | Chen HJ et al. [84] |
2 | Direct sequencing | Tissue N = 14 | 0 | 50 | Kosaka et al. [75] |
3 | ARMS | Tissue N = 10 | - | 0 | Zhang et al. [85] |
ddPCR | - | 50 | |||
4 | Standard HRM | Tissue N = 146 | 0 | - | Hashida et al. [107] |
MEC-HRM | 13 | - | |||
5 | SABER | Tissue N = 28 | 7 | - | Sakai et al.[120] |
6 | Ion Torrent PGM NGS | Tissue N = 15 | - | 60 | Masago et al. [94] |
7 | ddPCR | Tissue N = 12 | 83.3 | - | Isobe K et al. [92] |
8 | MALDI-TOF MS | Tissue N = 54 | 7.1 | - | Su K.Y et al. [97] |
NGS | 14.3 | - | |||
9 | PNA-clamping PCR | Tissue N = 50 | - | 68 | Costa C et al. [110] |
10 | ddPCR | Tissue N = 78 | 6.4 | - | Xu et al. [93] |
11 | ACB-ARMS PCR | Tissue N = 27 | 22.2 | - | Zhao J et al. [83] |
12 | PNA-clamping PCR | Tissue N = 147 | 8.2 | - | Oh et al. [76] |
Direct sequencing | 0 | - | |||
13 | ddPCR | Tissue N = 373 | 79.9 | - | Watanabe M et al.[105] |
14 | Direct sequencing | Tissue + other clinical samples N = 280 | 0.3 | 1.05 | Inukai M et al. [77] |
Mutant-enriched PCR | 3.5 | 3.1 | |||
15 | TaqMan PCR | Tissue N = 129 | 35 | - | Rosell R et al. [122] |
16 | SARMS | Tissue N = 38 | 0 | - | Fujita Y et al. [86] |
Colony hybridisation | 79 | - | |||
17 | Direct sequencing | Tissue N = 98 | 2 | - | Sequist LV et al. [71] |
18 | Direct sequencing | Tissue+other clinical samples N = 1261 | 0.5 | - | Wu JY et al. [79] |
19 | NGS (Miseq/Hiseq2000/Hiseq2500) |
Tissue N = 209 | 0.48 | - | Hagemann IS et al.[108] |
20 | LNA-PCR sequencing | Tissue N = 155 | - | 62 | Yu HA et al. [111] |
21 | Direct sequencing | Tissue+other clinical samples N = 69 | - | 49 | Arcila ME et al. [80] |
RFLP-PCR | Tissue+other clinical samples N = 45 | - | 53 | ||
LNA-PCR sequencing | Tissue+other clinical samples N = 64 | - | 70 | ||
22 | TaqMan PCR | Tissue+other clinical samples N = 15 | - | 40 | Molina-Vila MA et al. [123] |
23 | AMRS | Tissue N = 609 | 0.8 | - | Mok TS et al. [87] |
24 | Direct sequencing | Tissue N = 74 | - | 1.35 | Soh J et al. [81] |
25 | Cobas(Roche)/ARMS (Qiagen) | Tissue N = 148 | - | 53 | Sequist LV et al. [101] |
26 | Cobas (Roche) | Tissue N = 222 | - | 62 | Janne PA et al. [21] |
27 | ARMS | Tissue N = 134 | 6.8 | 28.4 | Yu J et al. [124] |
28 | NGS (MiSeq) | Tissue = 15 | - | 73.3 | Paweletz et al. [95] |
29 | NGS (AmpliSeq cancer hotspot panel v2) | Tissue N = 43 | - | 79 | Belchis DA et al. [96] |
‘-‘: not reported